---
title: Avapritinib versus Placebo in Indolent Systemic Mastocytosis
date: '2024-02-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38320129/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240207170748&v=2.18.0
source: heidelberg[Affiliation]
description: Avapritinib in Indolent Systemic MastocytosisIn a randomized trial, patients
  with indolent systemic mastocytosis were treated with avapritinib or placebo along
  with supportive care. The trial primary end point was the change in mean total symptom
  scores at 24 weeks. Avapritinib-treated patients had a decrease in mean total symptom
  score of 15.6 points compared with 9.2 points in the placebo ...
disable_comments: true
---
Avapritinib in Indolent Systemic MastocytosisIn a randomized trial, patients with indolent systemic mastocytosis were treated with avapritinib or placebo along with supportive care. The trial primary end point was the change in mean total symptom scores at 24 weeks. Avapritinib-treated patients had a decrease in mean total symptom score of 15.6 points compared with 9.2 points in the placebo ...